Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $57.9K | $601.1K | $435.3K | $641.4K | $475.0K | $318.0K | $0 |
| Cost of revenue | $88.2K | $13.9K | $145.1K | $118.3K | $164.4K | $0 | $0 | $0 |
| Gross profit | −$88.2K | $44.0K | $456.0K | $317.0K | $477.0K | $475.0K | $318.0K | $0 |
| Gross margin | — | 76.0% | 75.9% | 72.8% | 74.4% | 100.0% | 100.0% | — |
| R&D | $7.1M | $4.8M | $2.8M | $3.7M | $8.2M | $8.9M | $10.2M | $14.4M |
| Operating income | −$9.6M | −$6.7M | −$3.8M | −$6.1M | −$12.8M | −$10.2M | −$13.8M | −$18.6M |
| EBITDA | −$6.7M | −$5.1M | −$2.8M | −$4.5M | −$9.5M | −$9.3M | −$13.7M | −$18.5M |
| Net income | −$7.6M | −$5.3M | −$3.1M | −$5.1M | −$10.8M | −$8.3M | −$11.2M | −$14.9M |
| Net margin | — | -9088.8% | -514.7% | -1162.1% | -1691.2% | -1741.9% | -3511.3% | — |
| EPS (diluted) | -0.03 | -0.02 | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $0 | $-0.02 | $-0.02–$-0.02 | 1 |
| 2028 | $0 | $-0.01 | $-0.01–$-0.01 | 1 |
| 2029 | $0 | $-0.01 | $-0.01–$-0.01 | 1 |
| 2030 | $0 | $-0.01 | $-0.01–$-0.01 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds ETXPF.
No tracked institution reports a position in ETXPF as of their last filing.
No one on the platform has traded ETXPF yet.
| $69M |
| — |
| MCURFMind Cure Health Inc. | $0.51 | +971.88% | $87M | — |
| MSSTFMindset Pharma Inc. | $0.54 | -0.37% | $55M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 70.1× sales vs its 253.9× historical median P/S.
Fair value ≈ $0.47 · price $0.13 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.